{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:24:31Z","timestamp":1773937471892,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hepatic fibrosis develops as a response to chronic liver injury, resulting in the formation of fibrous scars. This process is initiated and driven by collagen-producing activated myofibroblasts which reportedly express high levels of platelet derived growth factor receptor-\u03b2 (PDGFR\u03b2). We therefore regard PDGFR\u03b2 as an anchor for diagnosis and therapy. The Fibrobody\u00ae SP02SP26-ABD is a biparatopic VHH-construct targeting PDGFR\u03b2. Here, we explore its potential as a theranostic vector for liver fibrosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Specificity, cross-species binding, and cellular uptake of SP02SP26-ABD was assessed using human, mouse and rat PDGFR\u03b2 ectodomains and PDGFR\u03b2-expressing cells. Cellular uptake by PDGFR\u03b2-expressing cells was also evaluated by equipping the Fibrobody\u00ae with auristatinF and reading out in vitro cytotoxicity. The validity of PDGFR\u03b2 as a marker for active fibrosis was confirmed in human liver samples and 3 mouse models of liver fibrosis (DDC, CCl<jats:sub>4<\/jats:sub>, CDA-HFD) through immunohistochemistry and RT-PCR. After radiolabeling of DFO*-SP02SP26-ABD with <jats:sup>89<\/jats:sup>Zr, its in vivo targeting ability was assessed in healthy mice and mice with liver fibrosis by PET-CT imaging, ex vivo biodistribution and autoradiography.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>SP02SP26-ABD shows similar nanomolar affinity for human, mouse and rat PDGFR\u03b2. Cellular uptake and hence subnanomolar cytotoxic potency of auristatinF-conjugated SP02SP26-ABD was observed in PDGFR\u03b2-expressing cell lines. Immunohistochemistry of mouse and human fibrotic livers confirmed co-localization of PDGFR\u03b2 with markers of active fibrosis. In all three liver fibrosis models, PET-CT imaging and biodistribution analysis of [<jats:sup>89<\/jats:sup>Zr]Zr-SP02SP26-ABD revealed increased PDGFR\u03b2-specific uptake in fibrotic livers. In the DDC model, liver uptake was 12.15\u2009\u00b1\u20090.45, 15.07\u2009\u00b1\u20090.90, 20.23\u2009\u00b1\u20091.34, and 20.93\u2009\u00b1\u20094.35%ID\/g after 1,2,3 and 4 weeks of fibrogenesis, respectively, compared to 7.56\u2009\u00b1\u20090.85%ID\/g in healthy mice. Autoradiography revealed preferential uptake in the fibrotic (PDGFR\u03b2-expressing) periportal areas.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The anti-PDGFR\u03b2 Fibrobody\u00ae SP02SP26-ABD shows selective and high-degree targeting of activated myofibroblasts in liver fibrosis, and qualifies as a vector for diagnostic and therapeutic purposes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-024-06785-9","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T04:01:55Z","timestamp":1718683315000},"page":"3545-3558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Preclinical targeting of liver fibrosis with a 89Zr-labeled Fibrobody\u00ae directed against platelet derived growth factor receptor-\u03b2"],"prefix":"10.1007","volume":"51","author":[{"given":"Joey A.","family":"Muns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Schooten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rychon D. J.","family":"van Dasselaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvet E.","family":"Noordman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Adamzek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur C.","family":"Eibergen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebas D.","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sagel","family":"Cali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niels J.","family":"Sijbrandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Merkul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.P.","family":"van Bergen en Henegouwen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. Bart","family":"Takkenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"Verheij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stan F.J.","family":"van de Graaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart A.","family":"Nijmeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5939-9851","authenticated-orcid":false,"given":"Guus A.M.S.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"6785_CR1","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.3350\/cmh.2022.0367","volume":"29","author":"C Gofton","year":"2023","unstructured":"Gofton C, Upendran Y, Zheng M-H, George J. MAFLD: how is it different from NAFLD? Clin Mol Hepathol. 2023;29:S17\u201331. https:\/\/doi.org\/10.3350\/cmh.2022.0367.","journal-title":"Clin Mol Hepathol"},{"key":"6785_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrgastro.2013.197","volume":"10","author":"K Ray","year":"2013","unstructured":"Ray K. NAFLD \u2013 the next global epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:621. https:\/\/doi.org\/10.1038\/nrgastro.2013.197.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6785_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalkoholic fatty liver disease \u2013 meta-analytic assessment of prevalence, incidence and outcomes. Hepatol. 2016;64:73\u201384. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatol"},{"key":"6785_CR4","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","volume":"65","author":"PS Dulai","year":"2017","unstructured":"Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalkoholic fatty liver disease: systematic review and meta-analysis. Hepathol. 2017;65:1557\u201365. https:\/\/doi.org\/10.1002\/hep.29085.","journal-title":"Hepathol"},{"key":"6785_CR5","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","volume":"158","author":"RS Taylor","year":"2020","unstructured":"Taylor RS, Taylor RJ, Bayliss S, Hagstr\u00f6m H, Nasr P, Schattenberg JM, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic liver diseases: a systematic review and meta-analysis. Gastroenterol. 2020;158:1611\u2013e2512. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.043.","journal-title":"Gastroenterol"},{"key":"6785_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jcmgh.2023.09.008","volume":"17","author":"HY Kim","year":"2024","unstructured":"Kim HY, Sakane S, Eguileor A, Carvalho R, Weber G, Lee W, et al. The origin and fate of liver myofibroblasts. Cell Mol Gasteroenterol Hepatol. 2024;17:93\u2013106. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.09.008.","journal-title":"Cell Mol Gasteroenterol Hepatol"},{"key":"6785_CR7","doi-asserted-by":"publisher","first-page":"11567","DOI":"10.3748\/wjg.v21.i41.11567","volume":"21","author":"Y Lurie","year":"2015","unstructured":"Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gasteroenterol. 2015;21:11567\u201383. https:\/\/doi.org\/10.3748\/wjg.v21.i41.11567. (2015).","journal-title":"World J Gasteroenterol"},{"key":"6785_CR8","doi-asserted-by":"publisher","first-page":"755","DOI":"10.4254\/wjh.v15.i6.755","volume":"15","author":"C-Y Zhang","year":"2023","unstructured":"Zhang C-Y, Liu S, Yang M. Treatment of liver fibrosis: past, current and future. World J Hepathol. 2023;15:755\u201374. https:\/\/doi.org\/10.4254\/wjh.v15.i6.755.","journal-title":"World J Hepathol"},{"key":"6785_CR9","doi-asserted-by":"publisher","first-page":"679","DOI":"10.2016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP, Barton D, Hull D, Parker R, et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicenter, double-blind, randomized, placebo-controlled, phase 2 study. Lancet. 2016;387:679\u201390. https:\/\/doi.org\/10.2016\/S0140-6736(15)00803-X.","journal-title":"Lancet"},{"key":"6785_CR10","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"N Engl J Med"},{"key":"6785_CR11","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","volume":"18","author":"R Vuppalanchi","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gateroenterol Hepatol. 2021;18:373\u201392. https:\/\/doi.org\/10.1038\/s41575-020-00408-y.","journal-title":"Nat Rev Gateroenterol Hepatol"},{"key":"6785_CR12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1018\/nri1412","volume":"4","author":"TA Wynn","year":"2004","unstructured":"Wynn TA. Fibrotic disease and the T(H)1\/T(H)2 paradigm. Nat Rev Immunol. 2004;4:583\u201394. https:\/\/doi.org\/10.1018\/nri1412.","journal-title":"Nat Rev Immunol"},{"key":"6785_CR13","doi-asserted-by":"publisher","first-page":"167sr1","DOI":"10.1126\/scitranslmed.3004700","volume":"5","author":"SL Friedman","year":"2013","unstructured":"Friedman SL, Sheppard D, Duffield JS, Violette S. Therapy for fibrotic diseases: nearing the start line. Sci Transl Med. 2013;5:167sr1. https:\/\/doi.org\/10.1126\/scitranslmed.3004700.","journal-title":"Sci Transl Med"},{"key":"6785_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3389\/fphar.2017.00855","volume":"8","author":"X Li","year":"2017","unstructured":"Li X, Zhu L, Wang B, Yuan M, Zhu R. Drugs and targets in fibrosis. Front Pharmacol. 2017;8:855. https:\/\/doi.org\/10.3389\/fphar.2017.00855.","journal-title":"Front Pharmacol"},{"key":"6785_CR15","doi-asserted-by":"publisher","unstructured":"Distler JHW, Gy\u00f6rfi A-H, Ramanujam M, Whitfields ML, K\u00f6ningshoff M, Lafyatis R. Shared and distinct mechanisms of fibrosis. Nat. Rev. Rheumatol. 2019:15;705\u2009\u2013\u200930. https:\/\/doi.org\/10.1038\/s41584-019-0322-7.","DOI":"10.1038\/s41584-019-0322-7"},{"key":"6785_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1067-1927.2005.130102.x","volume":"13","author":"A Desmouli\u00e8re","year":"2005","unstructured":"Desmouli\u00e8re A, Chaponnier C, Gabbiani G. Tissue repair, contraction, and the myofibroblast. Wound Repair Regen. 2005;13:7\u201312. https:\/\/doi.org\/10.1111\/j.1067-1927.2005.130102.x.","journal-title":"Wound Repair Regen"},{"key":"6785_CR17","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.1018\/ncomms3823","volume":"4","author":"I Mederacke","year":"2013","unstructured":"Mederacke I, Hsu CC, Troeger J, Heubener P, Mu X, Dapito DH, et al. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. https:\/\/doi.org\/10.1018\/ncomms3823.","journal-title":"Nat Commun"},{"key":"6785_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397\u201311. https:\/\/doi.org\/10.1038\/nrgastro.2017.38.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"6785_CR19","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1016\/j.cell.2021.06.024","volume":"184","author":"MV Plikus","year":"2021","unstructured":"Plikus MV, Wang X, Sinha S, Forte E, Thompson SM, Herzog EL, et al. Fibroblasts: origins, definitions, and functions in health and disease. Cell. 2021;184:3852\u201372. https:\/\/doi.org\/10.1016\/j.cell.2021.06.024.","journal-title":"Cell"},{"key":"6785_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1055\/s-2001-17558","volume":"21","author":"R Bataller","year":"2001","unstructured":"Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis. 2001;21:437\u201351. https:\/\/doi.org\/10.1055\/s-2001-17558.","journal-title":"Semin Liver Dis"},{"key":"6785_CR21","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.addr.2017.07.010","volume":"121","author":"S Yazdani","year":"2017","unstructured":"Yazdani S, Bansal R, Prakash J. Drug targeting to myofibroblasts: implications for fibrosis and cancer. Adv Drug Deliv Rev. 2017;121:101\u201316. https:\/\/doi.org\/10.1016\/j.addr.2017.07.010.","journal-title":"Adv Drug Deliv Rev"},{"key":"6785_CR22","doi-asserted-by":"publisher","unstructured":"Higashi T, Friedman SL, Hoshida Y. Hepatic stellate cells as key target in liver fibrosis. Adv Drug Deliv Rev. 2017;121. https:\/\/doi.org\/10.1016\/j.addr.2017.05.007.","DOI":"10.1016\/j.addr.2017.05.007"},{"key":"6785_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-020-2938-9","volume":"587","author":"NC Henderson","year":"2020","unstructured":"Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanism to medicines. Nature. 2020;587:555\u201366. https:\/\/doi.org\/10.1038\/s41586-020-2938-9.","journal-title":"Nature"},{"key":"6785_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2147\/JEP.S265286","volume":"13","author":"TM Huisman","year":"2021","unstructured":"Huisman TM, Dieterich DT, Friedman SL. Experimental and investigational targeted therapies for the management of fibrosis in NASH: an update. J Exp Pharmacol. 2021;13:329\u201338. https:\/\/doi.org\/10.2147\/JEP.S265286.","journal-title":"J Exp Pharmacol"},{"key":"6785_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.3390\/biomedicines9040365","volume":"9","author":"A Zisser","year":"2021","unstructured":"Zisser A, Ipsen DH, Tveden-Nyborg P. Hepatic stellate cell activation and inactivation in NASH fibrosis \u2013 roles as putative treatment. Targets? Biomedicines. 2021;9:365. https:\/\/doi.org\/10.3390\/biomedicines9040365.","journal-title":"Biomedicines"},{"key":"6785_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.cytogfr.2004.03.006","volume":"15","author":"JC Bonner","year":"2004","unstructured":"Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004;15:255\u201373. https:\/\/doi.org\/10.1016\/j.cytogfr.2004.03.006.","journal-title":"Cytokine Growth Factor Rev"},{"key":"6785_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.mam.2017.11.008","volume":"62","author":"BM Klinkhammer","year":"2018","unstructured":"Klinkhammer BM, Floege J, Boor P. PDGF in organ fibrosis. Mol Aspects Med. 2018;62:44\u201362. https:\/\/doi.org\/10.1016\/j.mam.2017.11.008.","journal-title":"Mol Aspects Med"},{"key":"6785_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","volume":"62","author":"N Papadopoulos","year":"2018","unstructured":"Papadopoulos N, Lennartsson J. The PDGF\/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75\u201388. https:\/\/doi.org\/10.1016\/j.mam.2017.11.007.","journal-title":"Mol Aspects Med"},{"key":"6785_CR29","doi-asserted-by":"publisher","first-page":"e11021","DOI":"10.15252\/emmm.201911021","volume":"12","author":"EM Buhl","year":"2020","unstructured":"Buhl EM, Djudjaj S, Klinkhammer BM, Ermert K, Puelles VG, Lindenmeyer MT, et al. Dysregulated mesenchymal PDGFR-b drives kidney fibrosis. EMBO Mol Med. 2020;12:e11021. https:\/\/doi.org\/10.15252\/emmm.201911021.","journal-title":"EMBO Mol Med"},{"key":"6785_CR30","doi-asserted-by":"publisher","first-page":"123639","DOI":"10.1016\/j.ijbiomac.2023.123639","volume":"235","author":"R Wang","year":"2023","unstructured":"Wang R, Liu F, Chen P, Li S, Gu Y, Wang L, et al. Gomisin D alliviates liver fibrosis through targeting PDGFR\u03b2 in hepatic stellate cells. Int J Biol Macromol. 2023;235:123639. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123639.","journal-title":"Int J Biol Macromol"},{"key":"6785_CR31","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.119.239558","volume":"62","author":"GAMS Van Dongen","year":"2021","unstructured":"Van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, et al. The role of 89Zr-immuno-PET in navigating and derisking the development of biopharmaceuticals. J Nucl Med. 2021;62:438\u201345. https:\/\/doi.org\/10.2967\/jnumed.119.239558.","journal-title":"J Nucl Med"},{"key":"6785_CR32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/protein\/gzq058","volume":"23","author":"J Hopp","year":"2010","unstructured":"Hopp J, Hornig N, Zettlitz KA, Schwarz A, Fuss N, M\u00fcller D, et al. The effects of affinity and valency of an albumin-binding domain (ABD) on the half-life of a single chain diabody-ABD fusion protein. Protein Eng Des Sel. 2010;23:827\u201334. https:\/\/doi.org\/10.1093\/protein\/gzq058.","journal-title":"Protein Eng Des Sel"},{"key":"6785_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2353\/ajpath.2007.061133","volume":"171","author":"P Fickert","year":"2007","unstructured":"Fickert P, St\u00f6ger U, Fuchsbichler A, Moustafa T, Marschall H-U, Weiglein AH, et al. A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. Am J Pathol. 2007;171:525\u201336. https:\/\/doi.org\/10.2353\/ajpath.2007.061133.","journal-title":"Am J Pathol"},{"issue":"Suppl 1","key":"6785_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/0023677215571192","volume":"49","author":"D Scholten","year":"2015","unstructured":"Scholten D, Trebicka J, Liedtke C, Weiskirchen R. The carbon tetrachloride model in mice. Lab Anim. 2015;49(Suppl 1):4\u201311. https:\/\/doi.org\/10.1177\/0023677215571192.","journal-title":"Lab Anim"},{"key":"6785_CR35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/iep.12008","volume":"94","author":"M Matsumoto","year":"2013","unstructured":"Matsumoto M, Hada N, Sakamaki Y, Uno A, Shiga T, Tanaka C, et al. An improved mouse model that rapidly develops fibrosis in non-alkoholic steatohepatitis. Int J Exp Pathol. 2013;94:93\u2013103.","journal-title":"Int J Exp Pathol"},{"key":"6785_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41181-023-00210-6","volume":"8","author":"O Wegrzyniak","year":"2023","unstructured":"Wegrzyniak O, Zhang B, Rokka J, Rosestedt M, Mitran B, Cheung P, et al. Imaging of fibrogenesis in the liver by [18F]TZ-Z09591, an Affibody molecule targeting platelet derived growth factor receptor \u03b2. EJNMMI Radiopharm Chem. 2023;8:23. https:\/\/doi.org\/10.1186\/s41181-023-00210-6.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"6785_CR37","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1007\/s00259-023-06577-7","volume":"51","author":"Z Li","year":"2024","unstructured":"Li Z, Yang H, Li X, She T, Tao Z, Zhong Y, et al. Platelet-derived growth factor receptor-\u03b2-targeted positron emission tomography imaging for the noninvasive monitoring of liver fibrosis. Eur J Nucl Med Mol Imaging. 2024;51:1530\u201343. https:\/\/doi.org\/10.1007\/s00259-023-06577-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6785_CR38","doi-asserted-by":"publisher","first-page":"5525","DOI":"10.7150\/thno.57510","volume":"11","author":"K Xenaki","year":"2021","unstructured":"Xenaki K, Dorresteijn B, Muns JA, Adamzek K, Doulkeridou S, Houthoff HJ, et al. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remissions in mice. Theranostics. 2021;11:5525\u201338. https:\/\/doi.org\/10.7150\/thno.57510.","journal-title":"Theranostics"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06785-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06785-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06785-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:28:48Z","timestamp":1727760528000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06785-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6785"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06785-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"17 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JAM, ES, RD, YEN, KA, ACE, SC, NJS, EM, BN and GAMSD are employees of LinXis Biopharmaceuticals. Other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}